What role did lipitor's partnerships play in its growth following patent expiration?

How did partnerships help Lipitor maintain sales after its patent expired?

Lipitor's owners formed licensing deals and authorized generics with major manufacturers to keep revenue flowing once exclusivity ended. These partnerships allowed immediate production of generic atorvastatin while the brand retained some pricing power through authorized versions.

What licensing arrangements supported Lipitor's post-patent strategy?

Pfizer entered into a deal with Watson Pharmaceuticals to launch an authorized generic of Lipitor on day one of patent loss. Watson paid Pfizer a royalty on every sale, returning a portion of the generic market directly to the original developer.

Why did Pfizer choose this approach over letting competitors in exclusively?

By authorizing generics through partners, Pfizer avoided a complete price collapse that occurs when multiple independent generics flood the market. The company kept a controlled share of the market and collected ongoing royalties instead of losing 80-90% of brand sales overnight.

What happened to Lipitor sales numbers after the 2011 patent loss?

Brand sales fell sharply but did not zero out. Through the authorized generic arrangement, Pfizer still received revenue from Watson's sales and retained some brand loyalty among patients who stayed on the originator product.

Can similar strategies work for other drugs facing patent cliffs?

Yes. Many companies now routinely use authorized generics as a defense mechanism against full generic erosion. This practice continues to and continues to appear in pipeline planning and patent disputes.